Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study

被引：17

作者：

Fairman, Jeff ^{[2
]}

Moore, Joseph ^{[3
]}

Lemieux, Mathieu ^{[3
]}

Van Rompay, Koen ^{[3
]}

Geng, Yongzhi ^{[3
]}

Warner, John ^{[2
]}

Abel, Kristina ^{[1
,3
]}

机构：

[1] Univ Calif Davis, Dept Internal Med, Div Infect Dis, Sch Med, Davis, CA 95616 USA

[2] Juvaris BioTherapeut Inc, Burlingame, CA USA

[3] Univ Calif Davis, California Natl Primate Res Ctr, Davis, CA 95616 USA

来源：

HUMAN VACCINES | 2009年 / 5卷 / 03期

关键词：

HIV; vaccine; adjuvant; SIMIAN IMMUNODEFICIENCY VIRUS; T-CELL RESPONSES; PLASMACYTOID DENDRITIC CELLS; ADAPTIVE IMMUNE-RESPONSE; INNATE IMMUNITY; IMMUNOLOGICAL MEMORY; NONHUMAN-PRIMATES; VIRAL-INFECTION; AIDS VACCINE; CPG MOTIFS;

D O I：

10.4161/hv.5.3.6589

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

This pilot study tested the immunogenicity of a novel cationic liposome-DNA complex (CLDC) immunomodulatory vaccine adjuvant. Combined with a specific antigen, CLDC enhanced anti-SIV immune responses induced by various SIV vaccine candidates. Rhesus macaques immunized in the presence of CLDC developed stronger SIV-specific T and B cell responses compared to animals immunized without CLDC. These differences persisted and resulted in better memory responses after an in vivo boost of the animals several months later with whole AT-2 inactivated SIVmac239. Thus, CLDC should be explored further as a potential immunomodulatory adjuvant in HIV vaccine design.

引用

页码：141 / 150

页数：10

共 57 条

[1] Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses [J].

Abel, K ;

Pahar, B ;

Van Rompay, KKA ;

Fritts, L ;

Sin, C ;

Schmidt, K ;

Colón, R ;

McChesney, M ;

Marthas, ML .

JOURNAL OF VIROLOGY, 2006, 80 (13) :6357-6367

[2] Recognition of pathogen-associated molecular patterns by TLR family [J].

Akira, S ;

Hemmi, H .

IMMUNOLOGY LETTERS, 2003, 85 (02) :85-95

[3] Targeting dendritic cells with antigen-containing liposomes: antitumour immunity [J].

Altin, JG ;

van Broekhoven, CL ;

Parish, CR .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (11) :1735-1747

[4] Liposomal vaccines - targeting the delivery of antigen [J].

Altin, Joseph G. ;

Parish, Christopher R. .

METHODS, 2006, 40 (01) :39-52

[5] Dendritic cells and the control of immunity [J].

Banchereau, J ;

Steinman, RM .

NATURE, 1998, 392 (6673) :245-252

[6] Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation [J].

Betts, MR ;

Brenchley, JM ;

Price, DA ;

De Rosa, SC ;

Douek, DC ;

Roederer, M ;

Koup, RA .

JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 281 (1-2) :65-78

[7] HIV vaccine design and the neutralizing antibody problem [J].

Burton, DR ;

Desrosiers, RC ;

Doms, RW ;

Koff, WC ;

Kwong, PD ;

Moore, JP ;

Nabel, GJ ;

Sodroski, J ;

Wilson, IA ;

Wyatt, RT .

NATURE IMMUNOLOGY, 2004, 5 (03) :233-236

[8] CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity [J].

Chu, RS ;

Targoni, OS ;

Krieg, AM ;

Lehmann, PV ;

Harding, CV .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) :1623-1631

[9] Prospects for an AIDS vaccine [J].

Desrosiers, RC .

NATURE MEDICINE, 2004, 10 (03) :221-223

[10] The challenge of viral immunity [J].

Doherty, Peter C. ;

Turner, Stephen J. .

IMMUNITY, 2007, 27 (03) :363-365

← 1 2 3 4 5 6 →